No article text was recorded for this version.
biomarker predictive insufficiency
Version 1 of 148 papers52 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Response to neoadjuvant treatment among rectal cancer patients in a population-based cohort
- Blog: Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: Circulating number of <scp>NK</scp> cells is associated with the response at 6 months
- Blog: Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
- Blog: Unexpected curative effect of PD-1 inhibitor in gastric cancer with brain metastasis: A case report
- Blog: Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer
- Blog: Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
- Blog: Exploring the predictive “psycho-biomarkers” for checkpoint immunotherapy in cancer
- Blog: Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
- Blog: Prognostic and immunotherapeutic significance of mannose receptor C type II in 33 cancers: An integrated analysis
- Blog: Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer
- Blog: Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial
- Blog: Maximizing Efficacy of Cancer Nanovaccines and Immune Cells Landscape in Responders and Non‐Responders to Immunotherapy
- Blog: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
- Blog: Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study
- Blog: Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer
- Blog: Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
- Blog: The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification
- Blog: Comprehensive pan-cancer analysis of FUTs family as prognostic and immunity markers based on multi-omics data
- Blog: Investigating the impact of regulatory B cells and regulatory B cell-related genes on bladder cancer progression and immunotherapeutic sensitivity
- Blog: Biological informed graph neural network for tumor mutation burden prediction and immunotherapy-related pathway analysis in gastric cancer
- Blog: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
- Blog: Identification of a TIGIT-expressing CD8+ T cell subset as a potential prognostic biomarker in colorectal cancer
- Blog: Predictors of Intravenous Immunoglobulin Non‐Responsiveness in Children With Kawasaki Disease
- Blog: Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer
- Blog: Quantitative Characterization of Macrophage, Lymphocyte, and Neutrophil Subtypes Within the Foreign Body Granuloma of Human Mesh Explants by 5-Marker Multiplex Fluorescence Microscopy
- Blog: Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer
- Blog: Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma
- Blog: Implications of the tumor immune microenvironment for staging and therapeutics
- Blog: A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer
- Blog: Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
- Blog: Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer
- Blog: The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC
- Blog: Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma
- Blog: A computational analysis of the oncogenic and anti-tumor immunity role of P4HA3 in human cancers
- Blog: Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
- Blog: Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma
- Blog: Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
- Blog: Weaning of immunosuppression in living-related liver transplantation.
- Blog: A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer.
- Blog: Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
- Blog: Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment
- Blog: Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures
- Blog: Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade
- Blog: Deep learning on CT scans to predict checkpoint inhibitor treatment outcomes in advanced melanoma
- Blog: Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials
- Blog: Machine Learning of Single Cell Transcriptomic Data From anti-PD-1 Responders and Non-responders Reveals Distinct Resistance Mechanisms in Skin Cancers and PDAC
- Blog: On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
- Blog: The combination of tumor mutational burden and T‐cell receptor repertoire predicts the response to immunotherapy in patients with advanced non–small cell lung cancer
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_biomarker_predictive_insufficiency_8af24495,
title = {biomarker predictive insufficiency},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/biomarker-predictive-insufficiency/rdr_8af244952620445fa3419d2d1db0be69},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}This exact version (version 1, frozen text):
@misc{lacuna_biomarker_predictive_insufficiency_8af24495_v1,
title = {biomarker predictive insufficiency},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/biomarker-predictive-insufficiency/rdr_8af244952620445fa3419d2d1db0be69/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}